Orexo (STO:ORX) said today that the European Medicines Agency granted marketing authorization for its Zubsolv rapidly-disintegrating treatment for opioid dependence. The buprenorphine and naloxone sublingual tablet is the first to be approved in Europe with six different strengths, according to the Sweden-based company. Get the full story at our sister site, Drug Delivery Business News. The post […]

WAREHAM (CBS) – One out of every four teenagers admits to misusing or abusing, a prescription drug. It’s a dangerous road that can lead to addiction. To prevent and treat drug-use in kids there is now a first-of-its-kind program tackling the issue head-on right at the pediatrician’s office. At Wareham Pediatrics, the Cat in the […]

A study published today in The Lancet found that two different therapies used to treat opioid use disorder – an extended-release naltrexone injection and a combination of buprenorphine and naloxone – have similar outcomes once patients get past the hurdle of starting treatment. This is the first study to compare the combination therapy and naltrexone head-to-head in […]

By Amy Orciari Herman Edited by Susan Sadoughi, MD Injectable extended-release naltrexone (Vivitrol) appears to be as safe and effective as daily oral buprenorphine-naloxone for treating opioid dependence, according to a Norway-based, noninferiority trial … (Source: Physician’s First Watch current issue)